SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 10, 2006
|
Array BioPharma Inc. |
|||||
|
(Exact name of registrant as specified in its charter) |
|||||
|
|
|
|
|
|
|
|
Delaware |
|
000-31979 |
|
84-1460811 |
|
|
(State or Other |
|
(Commission |
|
(IRS Employer |
|
|
Jurisdiction of |
|
File Number) |
|
Identification No.) |
|
|
Incorporation) |
|
|
|
|
|
|
|
|
|
|
|
|
|
3200 Walnut Street, Boulder, Colorado |
80301 |
|
|||
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
|||
Registrant’s telephone number, including area code: (303) 381-6600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS
On April 10, 2006, Array issued a press release announcing that AstraZeneca AB had selected a third compound for their small molecule MEK anti-cancer program, triggering a $1 million milestone payment from AstraZeneca to Array, the full text of which is attached hereto as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
99.1 Press release dated April 10, 2006 entitled “Array BioPharma Achieves Milestone for Selection of Third Compound for MEK Anti-cancer Program.”
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ARRAY BIOPHARMA INC. |
||
|
|
|
|
|
|
|
|
|
|
|
Date: April 10, 2006 |
By: |
|
/s/ Robert E. Conway |
|
|
|
Robert E. Conway |
|
|
|
|
Chief Executive Officer |
|
3
EXHIBIT INDEX
|
Exhibit No. |
|
|
|
|
|
|
|
99.1 |
|
Press release dated April 10, 2006 entitled “Array BioPharma Achieves Milestone for Selection of Third Compound for MEK Anti-cancer Program.” |
4